Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial

Authors:

Abstract
No abstract available
Funding Information
  • NewAmsterdam Pharma

This publication has 28 references indexed in Scilit: